RSS Feed Print
FDA approves THC trial for Alzheimer's disease
Lane Simonian
Posted: Wednesday, August 12, 2020 10:49 AM
Joined: 12/12/2011
Posts: 4854


The FDA just approved a trial using low doses of THC, melatonin, and turmeric for the potential treatment of Alzheimer's disease.  The THC will come from hemp oil and is less than the .3 percent federal limit.  That makes this trial possible.

https://www.proactiveinvestors.com/companies/news/217342/india-globalization-capital-stock-pops-after-cbd-based-hyalolex-drops-for-alzheimers-patients-launches-in-puerto-rico-217342.html

https://www.marketscreener.com/INDIA-GLOBALIZATION-CAPIT-57355601/news/India-Globalization-Capital-FDA-Approves-Initiation-of-IGC-s-Cannabinoid-Trial-on-Alzheimer-s-Pati-31101625/

The main focus in this trial is in improving behavioral and psychological symptoms of dementia.  A small, past trial for THC in Israel suggests this may be a good target:

https://pubmed.ncbi.nlm.nih.gov/26757043/

Turmeric/curcumin and melatonin have long been suggested as treatments for Alzheimer's disease because of their antioxidant properties, but have not seemed too effective so far.

This will be a good test to see the effects of THC (combined with turmeric and melatonin) on people with dementia.


Rfloyd
Posted: Tuesday, September 8, 2020 9:27 AM
Joined: 9/8/2020
Posts: 1


Finally the USA is far behind other countries in research due to pot past classification .
Lane Simonian
Posted: Thursday, December 3, 2020 11:41 AM
Joined: 12/12/2011
Posts: 4854


Yes.  Here is an update on the trial.


IGC Starts Phase 1 Study of Low-dose Cannabinoid in Alzheimer’s Patients

 

A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer's disease to test IGC-AD1, an investigational cannabis-based treatment being developed India Globalization Capital (IGC) Pharma, a subsidiary of IGC, according to a recent press release. In the placebo-controlled study, 12 participants will receive the medication over three 14-day periods, with the dose increasing in each period. The study primarily aims to assess the safety of IGC-AD1. Secondary goals include measuring pharmacokinetics (how a compound enters, transits, and leaves the body), how long the medication lasts in the body, and whether individuals process it differently based on minor changes in a liver enzyme called CYP450 2C9, which plays a key role in metabolizing numerous compounds. The company will also monitor the patients' dementia-related behavioral aspects to help guide later trial phases. IGC-AD1 combines small doses of cannabinoids — chemicals derived from cannabis — with other compounds into a formulation designed to help with Alzheimer's.